Inhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes
Hongmei Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Seng H. Cheng(Pfizer (United States))
Cited by 239
Related Papers
Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease
|Molecular Therapy|2009|169
Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease
|PLoS ONE|2010|72
Correction of the Nonlinear Dose Response Improves the Viability of Adenoviral Vectors for Gene Therapy of Fabry Disease
|Human Gene Therapy|2002|46
Correction of Disease Phenotype in Pompe Disease Knockout Mice Following Cationic Lipid-GL-67-Mediated Gene Therapy
|DNA and cell biology reports.|2025|0